1Novelli G, Margiord K, Sangiuolo F, et al. Pharmacogenetics of human andraogens and prostatic diseases. Pharmacogcnomics,2001,2(1) :65.
2Sim E, Payton M, Noble M, et al. An update on genetic, structural and functional studies of arylamine N - acetyltransferases in euearyotes and procaryotes J. Hum Mol Genet, 2000, 9 ( 16 ) :2435.
3March R. Pharmacogenomics: the genomics of drug response.Yeast, 2000. 17 (1) : 16.
4Hamet P. Genes and hypertension: where we are and where we should do. Clin Exp Hypertens, 1999,21(5 -6) : 947.
5Antonio R. Inventing the pharmacogenomics business . Am J Health Syst Pharm, 1999, 56 (1) : 40.
6Collins FS. Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics, 1999,54( 1 ) :41.
7Grant SFA. Pharmacogenetics and Pharmacogenomics: tailored drug therapy for the 21st century. Trends Pharmacal Sci, 2001,22(1) : 3.
9Krynetski EY, Evans WE. Pharmacogeneties as a molecular basis for individualized drug therapy: the thiopurine s -methyltrans-ferase paradigm. Pharm Res, 1999, 16(3) : 342.
